Hardik Shah
2026.06.24 11:15

๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $Viking Therap(VKTX.US) Viking Therapeutics Launches Phase 1 Trial for New Weight-Loss Drug VK3019

๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:

โžค ๐•๐ข๐ค๐ข๐ง๐  ๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ initiated a ๐๐ก๐š๐ฌ๐ž ๐Ÿ trial of weight-loss candidate VK3019.

โžค VK3019 is a ๐๐ฎ๐š๐ฅ ๐š๐ฆ๐ฒ๐ฅ๐ข๐ง and ๐œ๐š๐ฅ๐œ๐ข๐ญ๐จ๐ง๐ข๐ง receptor agonist (DACRA).

โžค Trial follows ๐…๐ƒ๐€ clearance of VK3019's Investigational New Drug application.

โžค Study will evaluate ๐ฌ๐š๐Ÿ๐ž๐ญ๐ฒ, ๐ญ๐จ๐ฅ๐ž๐ซ๐š๐›๐ข๐ฅ๐ข๐ญ๐ฒ, and pharmacokinetics in adults with BMI โ‰ฅ 30.

โžค Exploratory assessments include changes in ๐›๐จ๐๐ฒ ๐ฐ๐ž๐ข๐ ๐ก๐ญ after a single dose.

โžค Preclinical data showed up to ๐Ÿ–% ๐›๐จ๐๐ฒ-๐ฐ๐ž๐ข๐ ๐ก๐ญ reduction within 72 hours in animal studies.

โžค Viking is also conducting ๐๐ก๐š๐ฌ๐ž ๐Ÿ‘ VANQUISH trials for obesity drug VK2735.

โžค Company plans to launch a ๐๐ก๐š๐ฌ๐ž ๐Ÿ‘ trial of oral VK2735 later in 2026.

๐Ÿ‘‰ ๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ:

โžค VK3019 expands Viking's pipeline in the rapidly growing ๐จ๐›๐ž๐ฌ๐ข๐ญ๐ฒ treatment market.

โžค DACRA therapies could complement ๐†๐‹๐-๐Ÿ and GLP-1/GIP weight-loss medicines.

โžค Success could provide additional ๐ฅ๐จ๐ง๐ -๐ญ๐ž๐ซ๐ฆ ๐ฐ๐ž๐ข๐ ๐ก๐ญ-๐ฆ๐š๐ง๐š๐ ๐ž๐ฆ๐ž๐ง๐ญ options for patients.

๐Ÿ‘‰ ๐„๐ฑ๐ฉ๐ž๐ซ๐ญ ๐’๐ญ๐š๐ญ๐ž๐ฆ๐ž๐ง๐ญ:

โžค "The initiation of VK3019's Phase 1 study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians." โ€” ๐๐ซ๐ข๐š๐ง ๐‹๐ข๐š๐ง, Ph.D., Chief Executive Officer of Viking Therapeutics.

โžค "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management." โ€” ๐๐ซ๐ข๐š๐ง ๐‹๐ข๐š๐ง.

โžค "Broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss." โ€” ๐๐ซ๐ข๐š๐ง ๐‹๐ข๐š๐ง.

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.